-
1 Comment
Catalyst Biosciences, Inc is currently in a long term downtrend where the price is trading 23.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.9.
Catalyst Biosciences, Inc's total revenue rose by inf% to $2M since the same quarter in the previous year.
Its net income has dropped by 38.9% to $-19M since the same quarter in the previous year.
Finally, its free cash flow fell by 173.8% to $-22M since the same quarter in the previous year.
Based on the above factors, Catalyst Biosciences, Inc gets an overall score of 2/5.
| Industry | Biotechnology |
|---|---|
| ISIN | None |
| Sector | Healthcare |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Beta | nan |
|---|---|
| Market Cap | 292M |
| PE Ratio | None |
| Target Price | 22 |
| Dividend Yield | None |
Crescent Biopharma, Inc. operates as a biotechnology company dedicated to advancing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors. The company was incorporated in 2024 and is based in USA.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CBIO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
